Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.

Introduction: Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial. Methods: We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was concluded in most countries. Data collection was anonymous via a web-based instrument. Ten countries participated. Results: 630/1095 (57.6%) of the included patients received AIT. Compared to patients without AIT, those treated with AIT had a reduced risk ratio (RR) for COVID-19 lower respiratory symptoms (RR 0.78, 95% CI: 0.6703-0.9024; p = 0.001662) and need for oxygen therapy (RR 0.65, 95% CI: 0.4217-0.9992; p = 0.048). In adherent patients on maintenance sublingual immunotherapy/subcutaneous immunotherapy (SLIT/SCIT) the RR reduction was larger [RR = 0.6136 (95% CI 0.4623-0.8143; p < 0.001) and RR: 0.3495 (95% CI 0.1822-0.6701; p < 0.005), respectively]. SLIT was slightly more effective (NS). We excluded age, comorbidities, level of health care attendance, and type of allergic disorder as confounders, although asthma was related to a higher frequency of severe disease. When analyzing patients with allergic asthma (n = 503) the RR reduction favoring AIT was more pronounced with 30% for lower respiratory symptoms or worse (RR 0.6914, 95% CI 0.5264 to 0.9081, p = 0.0087) and 51% for need of oxygen therapy or worse (RR 0.4868, 95% CI 0.2829-0.8376, p = 0.0082). Among severe allergic patients treated with biologics (n = 24) only 2/24 needed oxygen therapy. There were no critical cases among them. Conclusion: In our registry AIT was associated with reduced COVID-19 severity.

Diretriz Latino-americana sobre o Diagnóstico e Tratamento da Alergia Ocular ­ Em nome da Sociedade Latinoamericana de Alergia, Asma e Imunologia (SLAAI) / Latin American Guideline on the Diagnosis and Treatment of Ocular Allergy ­ On behalf of the Latin American Society of Allergy, Asthma and Immunology (SLAAI)

A alergia ocular, também conhecida como conjuntivite alérgica (CA), é uma reação de hipersensibilidade mediada por imunoglobulina E (IgE) do olho desencadeada por aeroalérgenos, principalmente ácaros da poeira doméstica e pólen de gramíneas. Os sintomas geralmente consistem em prurido ocular ou periocular, lacrimejamento e olhos vermelhos que podem estar presentes durante todo o ano ou sazonalmente. A alergia ocular tem frequência elevada, é subdiagnosticada e pode ser debilitante para o paciente. É potencialmente danosa para a visão, nos casos em que ocasiona cicatrização corneana grave, e na maioria dos pacientes associa-se a outros quadros alérgicos, principalmente rinite, asma e dermatite atópica. É classificada em conjuntivite alérgica perene, conjuntivite alérgica sazonal, ceratoconjuntivite atópica e ceratoconjuntivite vernal. O diagnóstico procura evidenciar o agente etiológico e a confirmação se dá pela realização do teste de provocação conjuntival. O tratamento baseia-se em evitar o contato com os desencadeantes, lubrificação, anti-histamínicos tópicos, estabilizadores de mastócitos, imunossupressores e imunoterapia específica com o objetivo de obter o controle e prevenir as complicações da doença.

Ocular allergy, also known as allergic conjunctivitis, is an immunoglobulin E-mediated hypersensitivity reaction of the eye triggered by airborne allergens, primarily house dust mites and grass pollen. Symptoms usually consist of ocular or periocular itching, watery eyes, and red eyes that may be present year-round or seasonally. Ocular allergy has a high frequency, is underdiagnosed, and can be debilitating for the patient. It is potentially harmful to vision in cases of severe corneal scarring, and in most patients, it is associated with other allergic conditions, especially rhinitis, asthma, and atopic dermatitis. It is classified as perennial allergic conjunctivitis, seasonal allergic conjunctivitis, atopic keratoconjunctivitis, and vernal keratoconjunctivitis. Diagnosis seeks to identify the etiologic agent, and confirmation is given by conjunctival provocation testing. Treatment is based on avoiding contact with triggers, lubrication, topical antihistamines, mast cell stabilizers, immunosuppressants, and specific immunotherapy with the aim of achieving control and preventing disease complications.

Contaminación atmosférica en América Latina: impacto en la salud Y regulación actual - reporte del grupo del Comité de Aerobiología de la Sociedad Latinoamericana de Asma, Alergia e Inmunología / Atmospheric pollution in Latin America: impact on health and current regulation - report of the Aerobiology Committee of the Latin American Society of Asthma, Allergy and Immunology

La contaminación ambiental, en todas sus vertientes, tiene un efecto de enormes dimensiones no sólo sobre la existencia del planeta, sino también sobre la salud de la humanidad. América Latina es una región privilegiada ambientalmente, debido a su gran acervo de patrimonio natural, biodiversidad y posibilidades de provisión de servicios ambientales. Pero, a su vez, es una de las regiones más urbanizadas del orbe, con las afectaciones y presión al medio ambiente que esto implica, principalmente en la calidad del aire que se respira, derivadas de antiguos patrones productivos y de ocupación territorial, que se han agudizado como consecuencia del modelo de desarrollo predominante. Los efectos sobre la salud humana de diversas sustancias contaminantes están relacionados a procesos inflamatorios sobre mucosas y al aumento de la morbimortalidad en personas con enfermedades preexistentes, principalmente de los sistemas neurológico, cardiaco y respiratorio, en particular las enfermedades alérgicas respiratorias. La región latinoamericana enfrenta importantes problemas ambientales, determinados por los patrones de uso de sus recursos naturales, los sistemas de producción, los hábitos de consumo de las poblaciones humanas y la regulación gubernamental ambiental, que en muchos casos es laxa o pobremente implementada por los gobiernos en turno.

Air quality, in all its dimensions, has a major effect not only on the existence of the planet, but also on human health. Latin America is an environmentally privileged region, due to its great wealth of natural heritage, biodiversity and possibilities of provision of environmental services. But, at the same time, it is one of the most urbanized regions in the world, with the effects and pressure on the environment that this implies, mainly in the air quality, due to patterns of production and of territorial occupation, which they have exacerbated as a result of the predominant development model. The effects of diverse pollutant substances on the human health are related to inflammatory processes on mucous membranes and to increased morbidity and mortality in people with pre-existing diseases, especially of the neurological, cardiac and respiratory systems, in particular respiratory allergic illnesses. The Latin American region faces important environmental problems determined by the patterns of use of its natural resources, systems of production, habits of consumption of the human populations, and environmental governmental regulation, which is often lax or poorly implemented by the local authorities.

New concepts of histamine receptors and actions.

Histamine and antihistamines are so deeply woven into the fabric of allergic diseases that it is sometimes difficult to see how this field could advance beyond our current, potent histamine H1-receptor drugs. Investigations of other actions of histamine and the identification of H2, H3, and now H4 receptors have suddenly reignited the search for new mono- and multi-receptor-specific agonists and antagonists. There is great excitement due to preliminary findings that H3 receptors act as neural inhibitory autoreceptors, and H4 receptors might modulate immune cell functions.